IP Library Granted Patent US 7,906,133
Granted Patent B2
US 7,906,133 · App. 11/127,499 · Granted Mar 15, 2011

Optimized dosing for drug coated stents

Assignee: Boston Scientific Scimed, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,133
App. No.
11/127,499
Granted
Mar 15, 2011
Kind
B2
Abstract

The inventors have found that both the drug dose and drug release profiles are significant factors for the safety and efficacy of drug coated stents. The inventors have identified optimum dosing and release kinetics for drug coated stents. In particular, the inventors have determined dosing and release kinetics that permit the delivery of the lowest effective drug dosage, thus enhancing patient safety and minimizing any side effects from the drug.

Claims (21)

1. A drug coated stent comprising:

a structural member insertable into a body lumen of a patient; and

a drug coated onto at least a portion of said structural member;

wherein about 60 micrograms or less than 60 micrograms of the drug is released within ten days after insertion into the body lumen of the patient and

the release rate is maximized between 24 hours and three days.

2. The drug coated stent of claim 1 , wherein said drug comprises paclitaxel.

3. The drug coated stent of claim 1 , wherein said drug is incorporated into a polymer carrier coated onto at least a portion of said structural member.

4. The drug coated stent of claim 3 , wherein said polymer comprises styrene.

5. The paclitaxel coated stent of claim 2 , wherein about 20 micrograms or less than 20 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

6. The paclitaxel coated stent of claim 2 , wherein about 15 micrograms or less than 15 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

7. The paclitaxel coated stent of claim 2 , wherein about 10 micrograms or less than 10 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

8. The paclitaxel coated stent of claim 2 , wherein about 8 micrograms or less than 8 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

9. The paclitaxel coated stent of claim 2 , wherein about 6 micrograms or less than 6 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

10. The paclitaxel coated stent of claim 2 , wherein about 4 micrograms or less than 4 micrograms of paclitaxel is released from said stent ten days after exposure to an aqueous environment.

11. A paclitaxel coated stent comprising:

a structural member insertable into a body lumen of a patient; and

paclitaxel coated onto at least a portion of said structural member;

wherein about 10 micrograms or less than 10 micrograms of paclitaxel is released from said stent two days after exposure to an aqueous environment and

the release rate is maximized between 24 hours and three days.

12. The paclitaxel coated stent of claim 11 , wherein about 5 micrograms or less than 5 micrograms of paclitaxel is released from said stent two days after exposure to an aqueous environment.

13. The paclitaxel coated stent of claim 11 , wherein about 2 micrograms or less than 5 micrograms of paclitaxel is released from said stent two days after exposure to an aqueous environment.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2010
From: BARRY, JAMES J.; KAMATH, KALPANA R.
To: SCIMED LIFE SYSTEMS, INC.
Reel/Frame 024636/0423 →
CHANGE OF NAME Recorded Jul 6, 2010
From: SCIMED LIFE SYSTEMS, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 024636/0458 →
Continuity (2)
Continuation 10252848 · Sep 24, 2002
Related Publication 20050202061A1 · Sep 15, 2005